Literature DB >> 18507204

Characteristics of breast cancer patients with central nervous system metastases: a single-center experience.

Hakan Harputluoglu1, Omer Dizdar, Sercan Aksoy, Saadettin Kilickap, Didem S Dede, Yavuz Ozisik, Nilufer Guler, Ibrahim Barista, Ibrahim Gullu, Mutlu Hayran, Ugur Selek, Mustafa Cengiz, Faruk Zorlu, Gulten Tekuzman, Kadri Altundag.   

Abstract

The aim of this study was to assess the characteristics of breast cancer patients with central nervous system (CNS) metastases and factors associated with survival after development of CNS metastasis. One-hundred-forty-four patients with brain metastases were retrospectively analyzed. Median age at the time of brain metastasis diagnosis was 48.9. Median time between initial diagnosis and development of brain metastasis was 36 months. Fourteen cases had leptomeningeal involvement. Twenty-two patients (15.3%) had single metastasis. Ten percent of the patients had surgery, 94% had radiotherapy and 63% had chemotherapy. Median survival after development of brain metastasis was 7.4 months. Survival of patients with single metastasis was significantly longer than those with multiple metastases (33.5 vs. 6.5 months, p = 0.0006). Survival of patients who received chemotherapy was significantly longer than those who received radiotherapy alone (9.9 vs. 2 months, p < 0.0001). In multivariate Cox regression analyses, presence of single metastasis and application of chemotherapy were the only significant factors associated with better survival (p = 0.047 and p < 0.0001, respectively). Age at initial diagnosis or at the time of brain metastasis, time from initial diagnosis to development of brain metastasis, menopausal status, tumor stage, grade, hormone receptor or HER2 status individually were not associated with survival. In this study, survival after the diagnosis of CNS metastases appeared to be affected by patient characteristics rather than biologic characteristics of the tumor. This is probably secondary to the lack of effective treatment options in these patients and overall poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18507204     DOI: 10.1016/s0027-9684(15)31298-0

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  12 in total

1.  Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.

Authors:  Hee-Jun Kim; Seock-Ah Im; Bhumsuk Keam; Yu-Jung Kim; Sae-Won Han; Tae Min Kim; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Eui Kyu Chie; Wonshik Han; Dong-Wan Kim; Tae-You Kim; Dong-Young Noh; Dae Seog Heo; In Ae Park; Yung-Jue Bang; Sung Whan Ha
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

2.  A Fulminant Case of Leptomeningeal Carcinomatosis Secondary to Esophageal Adenocarcinoma.

Authors:  Banu Tasci Fresko; Meltem Topalgokceli Selam; Hatice Tuzlali; Burcin Batman; Oktar Asoglu
Journal:  J Gastrointest Cancer       Date:  2016-03

3.  Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.

Authors:  Romuald Le Scodan; Christophe Massard; Ludivine Jouanneau; Florence Coussy; Maya Gutierrez; Youlia Kirova; Florence Lerebours; Alain Labib; Emmanuelle Mouret-Fourme
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

4.  Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.

Authors:  Shaheenah Dawood; Ana M Gonzalez-Angulo
Journal:  Oncologist       Date:  2013-06-05

5.  Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.

Authors:  Thiele Kobus; Ioannis K Zervantonakis; Yongzhi Zhang; Nathan J McDannold
Journal:  J Control Release       Date:  2016-08-03       Impact factor: 9.776

6.  The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.

Authors:  Mustafa Oktay Tarhan; Lutfiye Demir; Isil Somali; Seyran Yigit; Cigdem Erten; Ahmet Alacacioglu; Hulya Ellidokuz; Ozgur Seseogullari; Yuksel Kucukzeybek; Alper Can; Ahmet Dirican; Vedat Bayoglu; Murat Akyol
Journal:  Clin Exp Metastasis       Date:  2012-08-23       Impact factor: 5.150

7.  The shifting landscape of metastatic breast cancer to the CNS.

Authors:  Matthew R Quigley; Olivia Fukui; Brandon Chew; Sanjay Bhatia; Steven Karlovits
Journal:  Neurosurg Rev       Date:  2012-12-22       Impact factor: 3.042

8.  Have changes in systemic treatment improved survival in patients with breast cancer metastatic to the brain?

Authors:  Carsten Nieder; Kirsten Marienhagen; Astrid Dalhaug; Jan Norum
Journal:  J Oncol       Date:  2008-09-23       Impact factor: 4.375

Review 9.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

10.  Prognostic scores in brain metastases from breast cancer.

Authors:  Carsten Nieder; Kirsten Marienhagen; Sabrina T Astner; Michael Molls
Journal:  BMC Cancer       Date:  2009-04-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.